Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FangzhouHKSE:06086 -2.67%11 PB Ratio is 2.94 as of Sep. 09, 2026, which is 89% below its 10-year median of 27.33. GuruFocus rates HKSE:06086 with a GF Score™ of 11/100. The stock has 3 warning signs investors should review. Among 611 Healthcare Providers & Services companies, Fangzhou ranks worse than 66.94% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-09), Fangzhou's share price is HK$0.73. Fangzhou's Book Value per Share for the quarter that ended in Dec. 2025 was HK$0.25. Hence, Fangzhou's PB Ratio of today is 2.94.
Good Sign:
Fangzhou Inc stock PB Ratio (=2.94) is close to 2-year low of 2.94.
The historical rank and industry rank for Fangzhou's PB Ratio or its related term are showing as below:
HKSE:06086'
s PB Ratio Range Over the Past 10 Years
Min: 2.92 Med: 27.33 Max: 51.9
Current: 2.92
During the past 5 years, Fangzhou's highest PB Ratio was 51.90. The lowest was 2.92. And the median was 27.33.
HKSE:06086's PB Ratio is ranked worse than 66.94% of 611
companies
in the Healthcare Providers & Services industry
Industry Median: 1.94
vs HKSE:06086: 2.92
During the past 12 months, Fangzhou's average Book Value Per Share Growth Rate was 21.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Fangzhou PB Ratio Related Terms
Fangzhou PB Ratio Historical Data
* Premium members only.
The historical data trend for Fangzhou's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Fangzhou's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fangzhou PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fangzhou's PB Ratio distribution charts can be found below:
* The bar in red indicates where Fangzhou's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Fangzhou's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Fangzhou (HKSE:06086) has a PB Ratio of 2.94 as of Sep. 09, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Fangzhou and its competitors. This is 89% below median its historical median of 27.33. Over the past decade, Fangzhou's PB Ratio has ranged from 2.92 to 51.90. According to the industry distribution chart, Fangzhou ranks #409 out of 611 companies in the Healthcare Providers & Services industry, placing it in the top 66.9%.
Is Fangzhou's PB Ratio too high?
Fangzhou's current PB Ratio of 2.94 is 89% below median its 10-year median of 27.33. Over the past 10 years, this metric has ranged from a low of 2.92 to a high of 51.90. The Healthcare Providers & Services industry median PB Ratio is 1.94. Fangzhou's value of 2.94 is 51.5% above this industry median. Based on the distribution chart, Fangzhou ranks #409 out of 611 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Fangzhou has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Fangzhou's PB Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Fangzhou ranks #409 out of 611 companies for PB Ratio. This places Fangzhou in the lower half of its industry. The industry median PB Ratio is 1.94. Fangzhou's value of 2.94 is 51.5% above this benchmark. Historically, Fangzhou's own PB Ratio has ranged from 2.92 to 51.90 over the past decade. While the company's 10-year median is 27.33 vs. the industry median of 1.94, Fangzhou has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 1.94, based on 611 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fangzhou's current PB Ratio of 2.94 is 51.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Fangzhou and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 1.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fangzhou's current PB Ratio is 2.94, which is 89% below median its own 10-year median of 27.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fangzhou stock overvalued right now?
Fangzhou (HKSE:06086) has a current PB Ratio of 2.94. The current PB Ratio is 2.94, which is 89% below median its 10-year median of 27.33 and 51.5% above the Healthcare Providers & Services industry median of 1.94. Fangzhou's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Fangzhou (HKSE:06086), the current PB Ratio is 2.94 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fangzhou Inc is a online chronic disease management platform in China. It has focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. The company provide comprehensive medical services and online retail pharmacy services through Jianke Platform. The principal segment of the group are online retail pharmacy services, comprehensive medical services, Wholesale and customized content and marketing solutions. Key revenue is generated from Online retail pharmacy services.
11GF Score
Get the complete analysis for HKSE:06086
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06086 has been successfully added to your 
